Sertraline
- Generic Name
- Sertraline
- Brand Names
- Zoloft
- Drug Type
- Small Molecule
- Chemical Formula
- C17H17Cl2N
- CAS Number
- 79617-96-2
- Unique Ingredient Identifier
- QUC7NX6WMB
- Background
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as Citalopram and Fluoxetine. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects.
...
- Indication
Sertraline is indicated for the management of major depressive disorder (MDD), post-traumatic stress disorder (PTSD), obsessive-compulsive disorder (OCD), panic disorder (PD), premenstrual dysphoric disorder (PMDD), and social anxiety disorder (SAD). Common off-label uses for sertraline include the prevention of post stroke depression, generalized anxiety di...
- Associated Conditions
- Binge Eating Disorder (BED), Bulimia Nervosa, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD)
- Associated Therapies
- -
ACE-D: Accelerating Cognition-guided Signatures to Enhance Translation in Depression: Clinical Trial
- First Posted Date
- 2024-05-10
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 160
- Registration Number
- NCT06408246
- Locations
- 🇺🇸
Stanford Psychiatry and Behavioral Sciences Department, Palo Alto, California, United States
🇺🇸University of Illinois at Chicago, Chicago, Illinois, United States
Efficacy and Safety of Sertraline in the Treatment of Maintenance Hemodialysis Patients With Depression
- First Posted Date
- 2023-11-09
- Last Posted Date
- 2023-11-09
- Target Recruit Count
- 125
- Registration Number
- NCT06124417
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
Sertraline Vs. Placebo in the Treatment of Anxiety in Children and AdoLescents with NeurodevelopMental Disorders
- First Posted Date
- 2023-10-13
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Anagnostou, Evdokia, M.D.
- Target Recruit Count
- 130
- Registration Number
- NCT06081348
- Locations
- 🇨🇦
Holland Bloorview Kids Rehabilitation Hospital, Toronto, Ontario, Canada
🇨🇦Alberta Children's Hospital - University of Calgary, Calgary, Alberta, Canada
🇨🇦University of Alberta-Glenrose, Edmonton, Alberta, Canada
The Effect of a Six Week Intensified Pharmacological Treatment for Bipolar Depression Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment.
- Conditions
- Interventions
- First Posted Date
- 2023-08-03
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Dr. Inge Winter
- Target Recruit Count
- 418
- Registration Number
- NCT05973786
- Locations
- 🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇩🇪Universitätsklinik für Psychiatrie und Psychotherapie Bielefeld, Bielefeld, Germany
🇩🇪University Hospital Frankfurt am Main - Goethe University, Frankfurt am Main, Germany
Sertraline Versus Escitalopram in South Asian Participants With Moderate to Severe Major Depressive Disorder
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- KRL Hospital, Islamabad
- Target Recruit Count
- 744
- Registration Number
- NCT05950061
- Locations
- 🇵🇰
KRL Hospital, Islamabad, Pakistan
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
- Conditions
- Interventions
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2024-01-26
- Lead Sponsor
- University of Texas at Austin
- Target Recruit Count
- 50
- Registration Number
- NCT05892744
- Locations
- 🇺🇸
Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas, United States
Sequenced Treatment Alternatives to Relieve Adolescent Depression (STAR-AD)
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-08-14
- Target Recruit Count
- 520
- Registration Number
- NCT05814640
- Locations
- 🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Province, China
Neural Markers of Treatment Mechanisms and Prediction of Treatment Outcomes in Social Anxiety
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Boston University Charles River Campus
- Target Recruit Count
- 240
- Registration Number
- NCT05683223
- Locations
- 🇺🇸
Center for Anxiety and Related Disorders at Boston University, Boston, Massachusetts, United States
Effect of Combined Antioxidant Therapy on Oxidative Stress Markers and Inflammatory Cytokines in Patients With Tinnitus
- First Posted Date
- 2022-12-12
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- University of Guadalajara
- Target Recruit Count
- 58
- Registration Number
- NCT05646693
- Locations
- 🇲🇽
Institute of Experimental and Clinical Therapeutics,, Guadalajara, Jalisco, Mexico
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
- Conditions
- Interventions
- First Posted Date
- 2022-11-02
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Dr. Inge Winter
- Target Recruit Count
- 1254
- Registration Number
- NCT05603104
- Locations
- 🇮🇱
Sheba Medical Center, Ramat Gan, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.